Gregory B. Barnett's most recent trade in Core Laboratories N.V. was a trade of 4,307 Common Shares done . Disclosure was reported to the exchange on April 1, 2022.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Core Laboratories N.V. | Gregory B. Barnett | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 4,307 | 33,907 (0%) | 0% | 0 | Common Shares | |
Core Laboratories N.V. | Gregory B. Barnett | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 4,307 | 0 | - | - | Restricted Shares | |
Core Laboratories N.V. | Gregory B. Barnett | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 14,507 | 0 | - | - | Restricted Shares | |
Core Laboratories N.V. | Gregory B. Barnett | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 14,507 | 29,673 (0%) | 0% | 0 | Common Shares | |
Core Laboratories N.V. | Gregory B. Barnett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 4,307 | 4,307 | - | - | Restricted Shares | |
Core Laboratories N.V. | Gregory B. Barnett | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.10 per share. | 01 Apr 2021 | 73 | 29,600 (0%) | 0% | 30.1 | 2,197 | Common Shares |